Funding agencies: This work was supported by the Basic Science Research Program through the National Research Foundation (NRF) of Korea as funded by the Ministry of Education, Science and Technology (MEST) (No. 2010-0029460).
Article first published online: 23 SEP 2011
Copyright © 2011 Movement Disorder Society
Volume 26, Issue 13, pages 2364–2370, November 2011
How to Cite
Lee, H.-W., Choi, J. and Suk, K. (2011), Increases of pentraxin 3 plasma levels in patients with Parkinson's disease. Mov. Disord., 26: 2364–2370. doi: 10.1002/mds.23871
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 22 NOV 2011
- Article first published online: 23 SEP 2011
- Manuscript Accepted: 15 JUN 2011
- Manuscript Revised: 6 JUN 2011
- Manuscript Received: 28 FEB 2011
- Parkinson's disease;
- Alzheimer's disease;
- mild cognitive impairment;
- pentraxin 3;
Pentraxin 3 is a prototypic long pentraxin. Pentraxin 3 is a soluble recognition receptor that is involved in innate immunity and the inflammatory response. Its expression is induced by proinflammatory signals. The aim of this study was to compare the plasma levels of pentraxin 3 in healthy subjects and patients with neurodegenerative disorders such as mild cognitive impairment, Alzheimer's disease, and Parkinson's disease (PD). Thirty-nine patients with mild cognitive impairment, 75 patients with Alzheimer's disease, 66 patients with PD, and 41 healthy elderly controls were recruited for this study. We performed an extensive battery of neuropsychological tests, including a Mini–Mental Status Examination, clinical dementia rating, and the Unified Parkinson's Disease Rating Scale. A variety of clinical information was collected from the administered semistructured questionnaire. Plasma pentraxin 3 levels were measured using a specific enzyme-linked immunosorbent assay. Plasma pentraxin 3 levels were significantly higher in the PD patients than in the patients with mild cognitive impairment and Alzheimer's disease and in the control subjects. Plasma pentraxin 3 levels in the PD patients were correlated with activities of daily living (r = 0.368; P = .003) and motor function (r = 0.358; P = .004). Plasma pentraxin 3 levels could be a new biochemical marker for PD, and they may be associated with the severity of motor dysfunction and other clinical symptoms in PD patients. © 2011 Movement Disorder Society